Skip to main content
. 2016 Jul 1;8(69):113295–113302. doi: 10.18632/oncotarget.10358

Figure 4. Combination of tamoxifen and C10 significantly inhibits MCF-7 cell viability/growth over Tamoxifen or C10 alone.

Figure 4

MCF-7 human breast cancer cells were plated onto a 96-well plate, for 72 hrs and then were treated with C10 (0, 250, or 500 μM), vehicle control (0.25% DMSO), tamoxifen (6 μg/ml) or a combination thereof. A MTT-based cell viability assay was then performed to assess cellular viability/growth at 72 hours. C10 further decreases cellular viability/growth in combination with tamoxifen in a dose-dependent manner. Error bars indicate SE. * indicates significant difference from DMSO 2.5%. One-Way ANOVA P=0.004, Tukey-Kramer post-hoc P<0.05. a indicates significantly different from Tamoxifen 0 µg/ml at respective C10 Dosages. One-Way ANOVA P=0.002, P=0.0001, P=0.00001, for C10 0mM, 0.25 mM, and 0.5 mM, respectively. Tukey-Kramer post-hoc P < 0.01 for all comparisons. Bars indicate significant differences as indicated. One-Way ANOVA P=0.003. Tukey-Kramer post-hoc P<0.05. Results presented are representative of at least n = 3 separate experiments.